Jan Poolman | Executive Advisor & Founder
CreaBacVac B.V.

Jan Poolman, Executive Advisor & Founder, CreaBacVac B.V.

Dr. Jan Poolman is former Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics resistant bacteria. In his role Jan is also responsible for external partnerships and clinical studies. He holds this function since 2011.
Jan is also a member of the Advisory Board for the Tuberculosis Vaccine Initiative (TBVI), and a member of the Editorial Board for the Expert Review of articles for the journal Vaccines.
From 1986 until 1996, Jan was Head of Vaccines R&D at the National Institute for Public Health and the Environment in the Netherlands (RIVM) and later the Netherlands Vaccines Institute (NVI). In 1997 he moved to industry and was appointed Head & Vice-President Bacterial Vaccines R&D at GSK Biologicals in Belgium. During his tenure, he contributed to the licensure of several vaccines: DTPaHBIPVHib Infanrix-Hexa, DTPaHBIPV Pediarix, Tdap Boostrix, HibMenC-TT Menitorix, 10-valent pneumococcal conjugate Synflorix, HibMenCY-TT Menhibrix, and ACWY-TT Nimenrix.
Jan began his career at the University of Amsterdam (UvA) where he obtained a Master’s degree in Chemistry in 1975 and a PhD on Meningococcal Surface Structure in 1981. In 1982 he was awarded an NIH post-doctoral fellowship research position at the University of Washington in Seattle, USA. In 1983 Jan returned to the UvA as Assistant-Professor Bacteriology. He held this position until 1985.
In his career Jan published over 250 articles in peer-reviewed journals.

Appearances:



Day 1 - Tuesday 14th October @ 14:00

AMR & Bacterial Vaccines Track Chair

Day 1 - Tuesday 14th October @ 15:45

AMR & Bacterial Vaccines Track Chair

Day 1 - Tuesday 14th October @ 16:00

From Farm to Fish: Species-Specific Strategies to Reduce Antibiotic Use in Livestock and Aquaculture

  • The role of combination vaccines and new vaccine platforms in preventing bacterial infections  
  • Case studies of successful vaccine interventions that led to measurable reductions in antibiotic use. 
  • Management and biosecurity strategies: recent progress in biosecurity protocols and livestock management practices  
  • Global standards and coordination efforts for AMR control in livestock.  
  • Species specific approaches: poultry, swine, aquaculture 
  • New vaccine platforms and combination approaches in veterinary health 
  • Biosecurity protocols and best practices for AMR control
last published: 10/Jul/25 11:25 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2025

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com

 

Otto Squire
Otto.Squire@terrapinn.com

 

TO SPEAK

 

Isla Sutherland
Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.